Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (161-170 of 234) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumorsOtto Soepenberg, Maja J A de Jonge, Alex Sparreboom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumorsFerry A L M Eskens, Maja J A de Jonge, Pankaj Bhargava, et al.
The Oncologist|April 5, 2007
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxelFrederike K Engels, Floris A de Jong, Alex Sparreboom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyPaul Lorigan, Jaap Verweij, Zsuzsa Papai, et al.
Lancet (London, England)|September 29, 2004
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialJaap Verweij, Paolo G Casali, John Zalcberg, et al.
Therapeutic Innovation & Regulatory Science|March 7, 2026
Challenges and Potential Solutions to Advance Global Cancer Drug DevelopmentAxel Glasmacher, Kim Lyerly, Birgit Wolf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)Stefan Sleijfer, Isabelle Ray-Coquard, Zsuzsa Papai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicityDiederik F S Kehrer, Annelies M Bos, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancerLia van Zuylen, John Bridgewater, Alex Sparreboom, et al.
Pageof 24

Showing results (161-170 of 234) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumorsOtto Soepenberg, Maja J A de Jonge, Alex Sparreboom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumorsFerry A L M Eskens, Maja J A de Jonge, Pankaj Bhargava, et al.
The Oncologist|April 5, 2007
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxelFrederike K Engels, Floris A de Jong, Alex Sparreboom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyPaul Lorigan, Jaap Verweij, Zsuzsa Papai, et al.
Lancet (London, England)|September 29, 2004
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialJaap Verweij, Paolo G Casali, John Zalcberg, et al.
Therapeutic Innovation & Regulatory Science|March 7, 2026
Challenges and Potential Solutions to Advance Global Cancer Drug DevelopmentAxel Glasmacher, Kim Lyerly, Birgit Wolf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)Stefan Sleijfer, Isabelle Ray-Coquard, Zsuzsa Papai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicityDiederik F S Kehrer, Annelies M Bos, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancerLia van Zuylen, John Bridgewater, Alex Sparreboom, et al.
Pageof 24